Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06213571 · ClinicalTrials.gov registry record · NA
Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas
A NA study of FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma and FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, sponsored by Mayo Clinic.
- Active
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06213571: Active NA study of FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma and FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, sponsored by Mayo Clinic.
NCT06213571 is a NA study of FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma and FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 80 participants, below the 196-participant average among 5 other FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06213571, a NA study of FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma and FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies how well a remotely delivered home-based exercise program for strength training works to positively impact endometrial cancer (EC) survivorship for patients with decreased cancer survivorship access. Cancer survivors in rural areas face barriers to supportive care, including geographic and environmental barriers to exercise and technology. Rural areas in the Midwest are underserved in terms of cancer care thus, it is essential to develop and test interventions that are scalable and can reach many individuals including those living in rural areas. Remotely-delivered exercise intervention approach allows for cancer survivors who may live far away from their primary treatment center to engage in supportive therapy via exercise interventions delivered in a sustainable context. In addition, historically black, hispanic and native endometrial cancer survivors have shorter survival and less access to survivorship care, so alternative models for healthcare delivery are needed in this underserved group. Information gained from this research may help determine whether utilizing a remotely delivered exercise program can positively impact EC survivorship for patients with decreased cancer survivorship access.
Primary Outcome
Assessed by the number of patients who complete 75% or more of the twice weekly exercise program.
Conditions Studied
Interventions
- OTHER Exercise Intervention
- OTHER Interview
- OTHER Health Promotion and Education
- OTHER Physical Performance Testing
- OTHER Exercise Counseling
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-03-22 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
What the registry record for NCT06213571 still lists
NCT06213571 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 196-participant average among 5 other FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma trials with a reported enrollment target (59% lower).
The record links to 4 conditions, with FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Exercise Intervention is the first listed.
NCT06213571 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06213571 about?
NCT06213571 is a clinical study titled "Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas". This clinical trial studies how well a remotely delivered home-based exercise program for strength training works to positively impact endometrial cancer (EC) survivorship for patients with decreased cancer survivorship access. Cancer survivors in rural areas face barriers to supportive care, includ...
What is the current status of trial NCT06213571?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-03-22. Estimated completion is 2026-03-31.
What conditions does trial NCT06213571 study?
This clinical trial studies the following conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v8, Stage IB Uterine Corpus Cancer AJCC v8.
What interventions are being tested in trial NCT06213571?
The interventions under investigation include: Exercise Intervention (OTHER), Interview (OTHER), Health Promotion and Education (OTHER), Physical Performance Testing (OTHER), Exercise Counseling (OTHER).
Who is sponsoring clinical trial NCT06213571?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06213571 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
RECRUITING
-
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Prediction of Recurrence Among Low Risk Endometrial Cancer Patients
ACTIVE NOT RECRUITING
-
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI